title: How cutaneous eruptions help to understand the mode of action of kinase inhibitors.
authors.forename: R
authors.initials: R
authors.lastname: Dummer
authors.forename: H
authors.initials: H
authors.lastname: Tsao
authors.forename: C
authors.initials: C
authors.lastname: Robert
mesh_terms: D003875:Drug Eruptions / Q000209:etiology*; D006801:Humans; D007211:Indoles / Q000009:adverse effects; D020930:MAP Kinase Kinase Kinases / Q000037:antagonists & inhibitors; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors; D012878:Skin Neoplasms / Q000139:chemically induced*; D013449:Sulfonamides / Q000009:adverse effects; D000077484:Vemurafenib
chemical_list: D007211:Indoles; D047428:Protein Kinase Inhibitors; D013449:Sulfonamides; D000077484:Vemurafenib; D048493:Proto-Oncogene Proteins B-raf; D020930:MAP Kinase Kinase Kinases